Skip to main content

Table 1 Characteristics of study cohort 1 and baseline statistics of CSF measurements

From: Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease

Cohort 1

 

DC (n = 72)

AD (n = 54)

p-value AD - DC

Age

69.71 ± 10.68

72.76 ± 10.91

0.1184*

Gender

0.0057$

Women

35 (48.6%)

40 (74.1%)

 

Men

37 (51.2%)

14 (25.9%)

 

CSF GPNMB [pg/ml]

9806 ± 4006

11270 ± 4957

0.0788#

APOE genotype

ε2/ε2

1

 

ε2/ε3

10

4

 

ε2/ε4

2

3

 

ε3/ε3

44

12

 

ε3/ε4

15

29

 

ε4/ε4

1

5

 

 ≥ 1 APOE ε4 allele, n (%)

18 (25%)

37 (68.5%)

<  0.0001$

 CSF p-Tau [pg/ml]*

47.47 ± 18.89

111.5 ± 46.66

<  0.0001#

 CSF t-Tau [pg/ml]*

257.1 ± 91.43

760.2 ± 310.2§

<  0.0001#

 CSF Aβ38 [pg/ml]*

2271 ± 997.3

2543 ± 889.4

0.0902#

CSF Aβ40 [pg/ml]*

6871 ± 3050

7614 ± 2875

0.1843#

CSF Aβ42 [pg/ml]*

709.2 ± 394

359.7 ± 141.6

<  0.0001#

CSF Aβ 42/40*

0.0994 ± 0.0231

0.0478 ± 0.0104

<  0.0001*

  1. The indicated parameters had been determined and partially reported before in a previous study [31]. §Some samples (20%) exceeded the upper limit of detection of the assay and were set to 1200 pg/ml. *Unpaired t-test, #Mann-Whitney test, or $Fisher’s exact test for differences between the diagnostic groups